Icon Genetics and Novoplant announce broad license agreement

Munich, November 13, 2003 - Icon Genetics AG, Munich, and Novoplant GmbH, Gatersleben, announced in Ocotber that the two companies entered into a broad licensing agreement that gives Novoplant an access to Icon's proprietary technology platforms, Transgene Operating Systems®, for manufacturing immune response proteins in green plants. The agreement provides Novoplant with a strategically needed freedom to operate in its core business area, animal health. The financial terms of the agreement are not disclosed. "Icon has developed new generation production platforms that are by far more effective and safe than those commercialized today, and they are more appropriate for the kind of products that Novoplant is developing. We believe that this agreement is an important step in mutually beneficial relationship with Novoplant, and I look forward to broadening our collaboration," said Dr. Yuri Gleba, CEO of Icon Genetics. "We believe Icon Genetics' proprietary gene transfer systems provide freedom to operate in otherwise restricted areas. Icon's Transgene Operating System® technology, combined with Novoplant technologies, is expected to provide a superior approach to rapid progress in our animal health research, product development and manufacturing," said Dr. Theodor Fahrendorf, CEO of Novoplant.

184 words/1,282 characters

About Icon Genetics AG
Icon Genetics is an integrated platform technology provider developing proprietary technologies and production hosts with application to a broad range of agricultural and pharmaceutical biotechnology products. Icon's new generation technologies of plant engineering (Transgene Operating Systems®) provide higher expression levels/yield, better expression control and higher biosafety. Corporate offices are headquartered in Munich, Germany and the Company's Research divisions are located in Halle and Freising, Germany. 

For more information about Icon Genetics AG, please visit the Company's website at www.icongenetics.com .

About Novoplant GmbH
Novoplant is a developer and producer of new antibody products for the veterinary and feed additives market. Oral applications of recombinant antibodies via the feed protect livestock and poultry from pathogens of the gastro-intestinal system, thus enhancing feed conversion and productivity without side effects. Novoplant introduces a new class of hyper-immune products into the market. The powerful plant based production system is essential to make the benefits of recombinant antibodies available at a competitive price. Novoplant is located in Gatersleben, Germany. 

For additional information about Novoplant GmbH, please visit the Company's website at www.novoplant.com .

Downloads: Text as rtf-file in "Presse Pool": www.biocommunications.net

Contact:

Icon Genetics AG
Maximilianstr. 38/40 
D- 80539 Munich, Germany
eMail: info@icongenetics.com
Web: www.icongenetics.com  

BIOCOMMUNICATIONS.net GmbH
Dr. Pablo Serrano
Brunnenstr. 128
D- 13355 Berlin, Germany
Tel: +49-(0)30-264921-30 
Fax: +49-(0)30-264921-11
Web: www.biocommunications.net 
eMail: service@biocommunications.net 

© BIOCOMMUNICATIONS.net GmbH, Brunnenstr. 128, D-13355 Berlin, Germany - Reprint free of charge, please supply copy